Toxoplasmosis: novel target to prevent tra... Scottish and Canadian researchers have identified a protein essential for the toxoplasmosis parasite to be transmitted. Targeting it might give rise to new treatments other parasitic diseases like … more ➔
Pulmocide raises £25m in Series B roundBritish inhaled anti-infectives specialist Pulmocide has bagged US$30.4m (€28.8m) from new and existing investors to bring its anti-RSV and anti-aspergillosis compounds into clinical testing. more ➔
Investors purchase ImegenThe investment groups Q-Growth Fund and Biolty purchased the majority of the Valencian biotechnology company Institute of Genomic Medicine (Imegen) for €10m. more ➔
Cell Medica bags €68,8 in Series C British Cell Medica has closed a 60£ (€68,8m) Series C financing to advance its pipeline of virus-specific Natural Killer T (NKT) cells in oncology and viral infection. more ➔
Avantium raised €103m in oversubscribed...According to main investor Sofinnova Partners, the Euronext IPO of Avantium, the front runner in renewable chemistry, was oversubscribed multiple times resulting in a market capitalisation of €277 … more ➔
NSCLC: Transgene launches cancer combo tes...Transgene has started Phase II efficacy testing of its therapeutic cancer vaccine TG4010 and Bristol-Myers Squibbs checkpoint inhibitor Opdivo (nivolumab) in non-squamous non-small cell lung cancer … more ➔
Allogenic stem cell transplant safe in hea...Belgian cell therapeutics specialist TiGenix NV announced positive top-line one-year results from its CAREMI stem cell study in acute myocardial infarction. more ➔
Pharnext partners with Galapagos Neurodegeneration specialist Pharnext SA and autoimmune disease expert Galapagos NV have inked an R&D contract in order to expand Pharnexts pleotherapy approach to new indications. more ➔
BerGenBio plans IPO and partners with MSD Norwegian BerGenBio ASA said it will go public at Oslo Børs and partnered with Merck & Co. for conducting Phase II combination studies of its oral Axl kinase blocker BGB324 with Mercks PD-1 inhibitor … more ➔
Breath Therapeutics cashes in €43,5mInhaled lung therapeutics specialist Breath Therapeutics Holding BV closed a Series A financing led by Gimv and Sofinnova. more ➔
